Haris Ali, MD, City of Hope, Duarte, CA, shares some insights into how disease-modifying agents may impact the role of transplantation in myelofibrosis (MF). Dr Ali first discusses the importance of clearly defining disease modification, and then goes on to explain how novel agents such as ruxolitinib have improved outcomes in patients undergoing transplantation, and future outlooks. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.